News

Arius Trop-2 targeting antibody has demonstrated a significant anti-tumor effect in animal models of human pancreatic cancer, inhibiting tumor growth by up to 100%. Subsequent testing showed efficacy

The amended license agreement expands the grant of rights to Immunosyn to include the exclusive worldwide right to market, sell, distribute and promote SF-1019 in its current form

Aradigm’s randomized, open-label, single-site Phase I trial evaluated arterial plasma pharmacokinetics and subjective acute cigarette craving when one of three nicotine doses (0.2mg, 0.4mg and 0.7mg) was administered

MedaSorb’s commercialization plan calls for CytoSorb to first enter the market in Europe and then in the US, followed by its pipeline of additional products. MedaSorb is initiating

The QuantRx biomedical female fertility test is a one-step lateral flow device that determines ovarian reserve indirectly by measuring follicle stimulating hormone (FSH) in first morning urine. The

NKTR-102 (Peg-irinotecan) is a pegylated form of irinotecan developed using Nektar’s innovative small molecule pegylation technology platform. NKTR-102 inhibited tumor growth by greater than 90% in mouse xenograft

Meda also obtains product rights, trademarks and right to the Recip name. Recipharm will continue as a contract manufacturer for Meda and is not part of the deal.

The Clinical Research Center of Cape Cod (CRCCC) is a medical research firm with products and services that support the pharmaceutical, biotechnology, diagnostic and genomics industries. John Cousins,

Pharmacokinetic results demonstrate that once-a-day orally-administered antimitotic agent ENMD-1198 has good pharmacokinetic (PK) parameters in cancer patients participating in a Phase I clinical study. In the first four